Serving a vast geographic region of great beauty, with rich multicultural and multiethnic diversity, tremendous scientific opportunity, and challenging health and socioeconomic disparities, the University of New Mexico Cancer Center and its consortium institutions - Lovelace Respiratory Research Institute, Los Alamos National Laboratory, and Sandia National Laboratories - are uniquely poised to make significant advances in cancer research and to serve our communities and our nation. As the only NCI Cancer Center within a 500 mile radius, the special characteristics of the UNM Cancer Center include: the multiethnic and multicultural populations that it serves - primarily Hispanic/Latino, American Indian, and non-Hispanic White - with their strikingly different patterns of cancer incidence, mortality, and disparity;the integration of regional scientific strengths in engineering, biotechnology, nanotechnology, radioisotopes, drug discovery, imaging, and high performance computing into its Research Programs and Shared Resources;and the extensive statewide outreach networks it has built for the delivery of cancer care, for culturally appropriate community-based education and participatory research, and for the participation of community oncologists in UNM Cancer Center clinical trials. Since the previous NCI P30 CCSG review in 2005, the Center's annual peer-reviewed research funding has increased 40% to over $46.8 million dollars in total costs, while annual funding from NCI increased 30% to over $13.8 million dollars. Intra-programmatic and inter-programmatic collaborations among the 117 members of the Center have increased markedly and range from 20-48% in each of the 4 Research Programs: Cancer Population Sciences, Cancer Biology and Biotechnology, Hematologic Malignancies, and Women's Cancers. Cancer Center members lead one of 9 NIH-funded Roadmap Centers for High Throughput Target Screening and Molecular Discovery {U54MH084690), one of 10 NIH-funded National Centers for Systems Biology (P50GM085273), one of 4 NSF/NCI Centers for Integrative Nanoscience and Microsystems Training (DGE0504276), one of 20 LLS Specialized Centers of Leukemia Research (LLS SCOR 7388-06), and an Interdisciplinary HPV Prevention Center (NIH U19AI084081). To assure that all New Mexicans have access to outstanding cancer diagnosis and treatment, the UNM Cancer Center opened its new 206,432 sq. ft., $90 million, Cancer Treatment and Clinical Research Facility in August 2009 which serves as the hub of the UNM Statewide Cancer Care Network. In collaboration with Siemens, this new facility contains a radioisotope production laboratory and experimental radiopharmacy, which will accelerate the Center's research programs. From 7/1/08-7/1/09, while maintaining its mission to the underserved and uninsured, the UNM Cancer Center ccrued 443 (17%) of the 2640 newly diagnosed patients treated at the Center to therapeutic clinical trials;51% of these patients were Hispanic or American Indian. Community affiliates accrued another 101 patients to UNM therapeutic trials. In addition, the Center had 845 accruals to non-intervention protocols in this time period. The overall goals of the UNM Cancer Center are to: 1) conduct outstanding transdisciplinary research in our laboratories, clinics and multiethnic and multicultural communities that builds upon our unique scientific and regional strengths;2) reduce the burden of cancer incidence and mortality by discovering the genetic, environmental, social, and behavioral factors that contribute to the distinct cancer patterns and cancer disparities in the peoples of the American Southwest;3) translate our scientific discoveries to novel diagnostic, screening, prevention, and therapeutic tools and clinical trials;and 4) provide access to outstanding cancer treatment and clinical trials for all New Mexicans.

Public Health Relevance

The University of New Mexico Cancer Center serves a vast geographic region in the American Southwest with striking ethnic and cultural diversity and significant cancer health disparities. Its transdisciplinary research programs focus on integrating advanced scientific capabilities in nanotechnology, drug discovery, radioisotopes and imaging, engineering, and computing with biomedical science to make novel discoveries and translate these discoveries to new and more effective cancer diagnostics and therapeutics. It is focused on the delivery of outstanding care to the peoples of the region and overcoming their cancer health disparities through community programs and partnerships.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA118100-10
Application #
8723064
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
2005-09-26
Project End
2015-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
10
Fiscal Year
2014
Total Cost
$1,876,081
Indirect Cost
$616,385
Name
University of New Mexico Health Sciences Center
Department
Pathology
Type
Schools of Medicine
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Flook, Adam M; Yang, Jianquan; Miao, Yubin (2014) Substitution of the Lys linker with the ?-Ala linker dramatically decreased the renal uptake of 99mTc-labeled Arg-X-Asp-conjugated and X-Ala-Asp-conjugated ?-melanocyte stimulating hormone peptides. J Med Chem 57:9010-8
Davies, Suzy; Holmes, Anna; Lomo, Lesley et al. (2014) High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol 33:402-10
Wu, Yang; Tapia, Phillip H; Jarvik, Jonathan et al. (2014) Real-time detection of protein trafficking with high-throughput flow cytometry (HTFC) and fluorogen-activating protein (FAP) base biosensor. Curr Protoc Cytom 67:Unit 9.43.
Morris, K T; Khan, H; Ahmad, A et al. (2014) G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br J Cancer 110:1211-20
Vaughan, Roger A; Gannon, Nicholas P; Garcia-Smith, Randi et al. (2014) ?-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro. Mol Cancer 13:14
Lu, Jie; Hathaway, Helen J; Royce, Melanie E et al. (2014) Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. Bioorg Med Chem Lett 24:725-30
Campen, Matthew J; Paffett, Michael L; Colombo, E Sage et al. (2014) Muscle RING finger-1 promotes a maladaptive phenotype in chronic hypoxia-induced right ventricular remodeling. PLoS One 9:e97084
Yang, Jianquan; Flook, Adam M; Feng, Changjian et al. (2014) Linker modification reduced the renal uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide. Bioorg Med Chem Lett 24:195-8
Hill, Jeff W; Thompson, Jeffrey F; Carter, Mark B et al. (2014) Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening. PLoS One 9:e96761
Scaling, Allison L; Prossnitz, Eric R; Hathaway, Helen J (2014) GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer 5:146-60

Showing the most recent 10 out of 123 publications